Cell cycle-related proteins

Cell cycle-related proteins constitute a broad class of enzymes, regulatory subunits, and checkpoint factors that orchestrate the orderly progression of cells through the division cycle [1][2]. Key members include cyclin-dependent kinases (CDKs), their activating cyclin partners, and various inhibitors like the Ink4 and Cip/Kip families, which together maintain genomic integrity and control cellular growth [2][3]. Deregulation of these proteins—often via overexpression of cyclins or loss of endogenous inhibitors—is a near-universal feature of human cancers, facilitating unchecked proliferation and tumor evolution [4]. Pharmacological intervention typically focuses on inhibiting specific CDKs (notably CDK4 and CDK6) or disrupting microtubule dynamics to trigger cell cycle arrest and subsequent apoptosis [5]. These therapies have become standard of care in several malignancies, such as hormone receptor-positive breast cancer, where they effectively stall the G1-S phase transition [6]. However, because these proteins are essential for the maintenance of normal proliferative tissues, their inhibition frequently results in clinical challenges such as hematological toxicities and immunosuppression [5][6]. Citations: [1] National Cancer Institute (NCI) Dictionary of Cancer Terms; [2] Malumbres & Barbacid (2009) Nature Reviews Cancer; [3] UniProt (Cell cycle control proteins); [4] Hanahan & Weinberg (2011) Cell; [5] StatPearls (CDK4/6 Inhibitors); [6] Finn et al. (2016) New England Journal of Medicine.

Other names

Cell cycle regulatorsCell cycle machineryMitotic regulatorsCell cycle control proteins

Inhibition of cyclin-dependent kinases (CDKs) to induce G1 phase arrest, stabilization or destabilization of microtubules to prevent mitotic progression, and inhibition of DNA polymerase or nucleotide synthesis to arrest the S phase.